Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development.
Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat various psychiatric disorders such as depression, anxiety, schizophrenia, and others. The process of antipsychiatric drug development typically involves several stages, including identifying potential drug targets, conducting preclinical research to test the safety and efficacy of potential drug candidates, and then moving on to clinical trials to further evaluate the drug’s effectiveness and safety in human subjects. Animal models and cellular models are commonly used in preclinical research for psychiatric drug development as they help study the behavioral and physiological effects of potential drug candidates, as well as investigate the underlying mechanisms of psychiatric disorders.
Neuropsychiatric disorders such as schizophrenia, major depressive disorder, bipolar disorder, and autism are so prevalent, begin early in life, and have a major impact on the worldwide disease burden that new therapeutic mechanisms have all but stalled. It is difficult to imagine major advances in pathophysiology or therapeutics without good animal models.
With extensive experience in the antipsychiatry industry, the Ace Therapeutics Psychiatry team understands the unique challenges and complexities of developing effective therapies for psychiatric disorders. By leveraging its expertise and resources, the company can develop animal models, cell models, multicellular models, pharmacokinetic/pharmacodynamic modeling, biomarker discovery, and more. These model development services are designed to offer researchers the tools and resources they need to optimize drug development and maximize success rates.
So far, Ace Therapeutics has established various animal models of mental illness through methods such as selective breeding, genetic engineering, brain injury, and environmental manipulation. Moreover, the company can also provide cellular models from high-quality sources for psychiatric pathology and drug discovery to enable researchers to study and model clinically important psychiatric disorders in relevant genetic and cellular environments.
- Depression Animal Models
Ace Therapeutics has developed a variety of animal models based on the etiology of depression, acute or chronic stress exposure, gene-environment interaction, exogenous glucocorticoid administration, and gene manipulation. These animal models of depression can be used to study the molecular and cellular pathways that may be crucial to the pathogenesis of depression.
- Schizophrenia Animal Models
Ace Therapeutics has developed more than 20 different animal models of schizophrenia based on developmental, drug-induced, lesion, and genetic manipulation. These models are very valuable preclinical tools that can be used to help you study the neurobiological basis of schizophrenia.
- Obsessive–compulsive Disorder Animal Models
Ace Therapeutics has developed multiple animal models of OCD through genetic, pharmacologically induced, behavior-based manipulation, and neurodevelopmental approaches that can be used to develop new therapeutic strategies for OCD and other related disorders.
- Eating Disorders Animal Models
Ace Therapeutics can provide some environmental and genetic animal models for studying eating disorders, including animal models of anorexia nervosa and animal models of bulimia nervosa/binge eating. These models accurately reproduce the alterations in feeding and neuroendocrine function that are unique to each eating disorder.
The field of psychiatric drug development is constantly evolving, and Ace Therapeutics is committed to staying at the forefront of innovation. In addition to mental illness models, Ace Therapeutics can also provide drug development services including antipsychotics screening services, pharmacokinetics analysis services, lead discovery and optimization services to help researchers dive deeper into psychiatry research and drug development. These services will enable researchers to explore new pathways, identify potential drug targets, and ultimately bring life-changing treatments to patients in need.
About Ace Therapeutics
With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative therapies that address unmet medical needs. From early-stage research to translational medicine, Ace Therapeutics offers tailored solutions to facilitate preclinical studies, enabling the transformation of promising concepts into life-changing treatments.
